John Bitner, MD
Otolaryngology · Layton, UTNPI 1336129543
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $175,142 of the $176,586 with a category attached, or 99.2%. AbbVie accounts for 99.5% of it on its own, with 7 other manufacturers making up the rest. Reporting peaked in 2021 at $132,901 and has fallen 95.9% since, to $5,495 in 2025. Among otolaryngology clinicians in UT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 100 payments — averaging $1765.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$176K
- Integra Lifesciences Corporation$423
- Galderma Laboratories, L.p.$151
- Revance Therapeutics, Inc.$74
- Merz North America, Inc.$57
- Apyx Medical Corporation$52
- plus $45 from 2 others
What the payments were for
- Speaking & faculty fees$175,14299%
- Food & beverage$1,0041%
- Education$170%
- Other$4230%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 89 | $175,784 |
| Integra Lifesciences Corporation | 1 | $423 |
| Galderma Laboratories, L.p. | 3 | $151 |
| Revance Therapeutics, Inc. | 1 | $74 |
| Merz North America, Inc. | 3 | $57 |
| Apyx Medical Corporation | 1 | $52 |
| Boston Scientific | 1 | $27 |
| TELA Bio, Inc. | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DuraSorb Monofilament Mesh$423
- BOTOX$120
How this compares
$176,586 in reported general payments places this provider in the 95th percentile of 104 otolaryngology providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ValacyclovirValacyclovir Hcl | 19 | $297 |
| Cephalexin | 34 | $208 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 28 | $109 |
| Ondansetron OdtOndansetron | 12 | $85 |
| Celecoxib | 26 | $40 |
| Prednisone | 16 | $29 |
| Gabapentin | 23 | $13 |
Paid to pharmacies, not to this prescriber.
Other otolaryngology in Layton
- Bryan RichardsLayton$6K
- Richard VanleeuwenLayton$2K
- Alexander RamirezLayton$2K
- Robert MellorLayton$2K
- Bryan WilcoxLayton$2K
- Steven MillerSalt Lake City$32K
- Michael WilsonSalt Lake City$16K
- Kevin WilsonDraper$13K
- Jerry SonkensSlc$12K
- Matthew DahlSalt Lake City$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.